News Release

Guide to ASH 2026: ECOG-ACRIN and PrECOG to spotlight blood cancer advances

Meeting Announcement

ECOG-ACRIN Cancer Research Group

New findings from blood cancer clinical trials and updates on ongoing studies by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will be presented at the  68th American Society of Hematology (ASH) Annual Meeting and Exposition. Highlights include a new analysis from the practice-changing E1910 phase 3 trial, which supported a U.S. Food and Drug Administration (FDA) approval of blinatumomab consolidation for certain B-cell acute lymphoblastic leukemia patients.   

The presentations are listed below by type and date. The ASH meeting will occur in person in New Orleans, Louisiana, on December 12–15, 2026, at the Ernest N. Morial Convention Center. Presentation titles link to the abstracts, which became publicly available on November 4. All times are Central Time.  

Oral Presentations 

Identifying patients with classic Hodgkin lymphoma who are at higher risk of poor outcomes remains a clinical challenge. In an analysis of two patient cohorts, one of which included participants in ECOG-ACRIN’s E2496 trial, overall survival was poorer among patients whose lymphoma cells had no detectable PRAME protein. These findings support further study of PRAME as a potential biomarker of high-risk disease. 

Relapse remains a concern for patients with newly diagnosed FLT3-mutated acute myeloid leukemia treated with midostaurin plus intensive chemotherapy. The randomized phase 2 PrE0905 trial compared this combination with gilteritinib plus intensive chemotherapy as an alternative. Initial results presented at ASH 2024 showed higher composite complete remission rates and more transplants in first remission with gilteritinib, but no improvement in the primary endpoint of post-induction FLT3 mutation-negative composite complete remission. With longer follow-up, gilteritinib also improved event-free survival compared with midostaurin. 

Blinatumomab is an established part of consolidation treatment with chemotherapy for certain patients with B-cell acute lymphoblastic leukemia—including patients in remission who test negative for measurable residual disease (MRD). ECOG-ACRIN’s E1910 trial supported its FDA approval in June 2024. In the new analysis, researchers used sequencing sensitive enough to detect one leukemia cell per million cells using bone marrow samples from trial participants whose MRD was undetectable by flow cytometry. Even among patients with no detectable leukemia by sequencing, adding blinatumomab to consolidation chemotherapy improved relapse-free and overall survival compared with chemotherapy alone. 

Abstract 1000 in Session 613 (entire session 4:30–6:00 PM) 

Poster Presentations (Trials in Progress) 

Abstract 1627 in Session 616 

Abstract 5794 in Session 654 

Related NCTN-Wide Trial in Progress 

ECOG-ACRIN is collaborating on a study designed to be the largest clinical trial of early-stage classic Hodgkin lymphoma ever conducted in the National Cancer Institute's National Clinical Trials Network (NCTN). With a target of 1,875 participants ages 5–60, it aims to improve outcomes and establish a consistent treatment approach across age groups. Pediatric and adult oncology investigators developed the study together. Study champions from the five U.S. cooperative groups are supporting nationwide recruitment.  

Presenter: Boyu Hu, MD (The University of Utah)  

ECOG-ACRIN Study Champions: Pamela Blair Allen, MD (Emory University) and Andrew M. Evens, DO, MSc (Rutgers Cancer Institute of New Jersey) 

Date and Time: Sunday, December 13, 6:00–8:00 PM 
Location: Hall F 

Abstract 3591 in Session 624 

Consult each abstract for study funding details. Presenters are available for media interviews under the ASH news embargo policy. 

About ECOG-ACRIN 

ECOG-ACRIN Cancer Research Group is one of the world’s leading scientific organizations, known for innovative multicenter clinical trials involving adults with cancer or at risk of developing it. Its expansive network of nearly 1,400 hospitals and cancer centers across the United States and around the world includes about 21,000 researchers and advocates. Its research is funded primarily by the National Cancer Institute, part of the U.S. National Institutes of Health. To learn more, visit www.ecog-acrin.org and follow us on X, Facebook, LinkedIn, YouTube, Instagram, and Bluesky, or call 215-789-3631. 

About PrECOG 

PrECOG, LLC is a cancer research organization that designs and conducts innovative oncology studies through industry partnerships and research networks. PrECOG focuses on trials that align with the scientific mission and research goals of the ECOG-ACRIN Cancer Research Group. To learn more, visit www.precogllc.org and follow us on X, Facebook, LinkedIn, YouTube, and Bluesky, or call 215-789-3631. 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.